JNJ-88545223 Phase 2 Study for Active Psoriatic Arthritis Initiated
Johnson & Johnson has initiated Phase 2 clinical trial for JNJ-88545223, aimed at evaluating its efficacy and safety in adults with active psoriatic arthritis compared to a placebo.
Asset / Drug
Drug and asset intelligence for Active Psoriatic with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.